Apellis Pharmaceuticals APLS

$ 27.4 -0.35%

Quarterly report 2024-Q3
added 11-05-2024

Apellis Pharmaceuticals Balance Sheet 2011-2024 | APLS

Annual Balance Sheet Apellis Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-252 M	-453 M	-447 M	-203 M	-195 M	-149 M	-149 M	-24.9 M	-36 M	-13.6 M	-4.76 M	-	-
Long Term Debt	93 M	92.7 M	189 M	359 M	143 M	25.4 M	26.4 M	-	-	-	-	-	-
Long Term Debt Current	6.44 M	5.62 M	4.12 M	3.68 M	2.61 M	1.67 M	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	289 M	25.5 M	26.6 M	-	-	-	-	-	-
Total Current Liabilities	248 M	168 M	132 M	128 M	65.8 M	17 M	6.55 M	-	-	-	-	-	-
Total Liabilities	594 M	590 M	683 M	756 M	355 M	42.6 M	33.2 M	3.64 M	3.2 M	1.08 M	677 K	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-2.84 B	-2.31 B	-1.66 B	-926 M	-581 M	-277 M	-149 M	-98.3 M	-71.1 M	-24.6 M	-13.8 M	-	-
Total Assets	789 M	760 M	882 M	961 M	389 M	204 M	182 M	27.4 M	38.2 M	14.3 M	5.2 M	-	-
Cash and Cash Equivalents	351 M	552 M	640 M	566 M	352 M	176 M	176 M	24.9 M	-	-	-	-	-
Book Value	195 M	170 M	199 M	205 M	34.2 M	161 M	149 M	23.8 M	35 M	13.2 M	4.52 M	-	-
Total Shareholders Equity	195 M	170 M	199 M	205 M	34.2 M	161 M	149 M	23.8 M	35 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Apellis Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	93.3 M	93.2 M	93.1 M	93 M	93 M	92.9 M	92.8 M	92.7 M	92.7 M	189 M	189 M	189 M	190 M	386 M	386 M	359 M	359 M	359 M	359 M	143 M	11.3 M	5.24 M	5.57 M	-	27 M	27 M	27 M	27 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	665 M	640 M	565 M	594 M	586 M	570 M	567 M	590 M	565 M	668 M	684 M	683 M	583 M	841 M	758 M	756 M	756 M	756 M	756 M	355 M	355 M	355 M	355 M	42.6 M	42.6 M	42.6 M	42.6 M	33.2 M	33.2 M	33.2 M	33.2 M	3.64 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-3 B	-2.94 B	-2.9 B	-2.84 B	-2.75 B	-2.61 B	-2.49 B	-2.31 B	-2.14 B	-1.95 B	-1.8 B	-1.66 B	-1.51 B	-1.31 B	-1.09 B	-926 M	-926 M	-926 M	-926 M	-581 M	-581 M	-581 M	-581 M	-277 M	-277 M	-277 M	-277 M	-149 M	-149 M	-149 M	-149 M	-98.3 M	-98.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	902 M	904 M	832 M	789 M	818 M	916 M	979 M	760 M	873 M	1 B	1.15 B	882 M	526 M	700 M	810 M	961 M	961 M	961 M	961 M	389 M	389 M	389 M	389 M	204 M	204 M	204 M	204 M	182 M	182 M	182 M	182 M	27.4 M	27.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	397 M	360 M	326 M	351 M	452 M	616 M	765 M	552 M	584 M	604 M	633 M	640 M	284 M	271 M	265 M	567 M	566 M	566 M	566 M	352 M	352 M	352 M	352 M	176 M	176 M	176 M	176 M	176 M	176 M	176 M	176 M	24.9 M	24.9 M	-	-	36 M	-	-	-	13.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	237 M	264 M	267 M	195 M	232 M	345 M	412 M	170 M	307 M	334 M	462 M	199 M	-57.3 M	-141 M	51.7 M	205 M	205 M	205 M	205 M	34.2 M	34.2 M	34.2 M	34.2 M	161 M	161 M	161 M	161 M	149 M	149 M	149 M	149 M	23.8 M	27.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	237 M	264 M	267 M	195 M	232 M	345 M	412 M	170 M	307 M	-334 M	462 M	199 M	-57.3 M	-141 M	51.7 M	205 M	205 M	205 M	205 M	34.2 M	34.2 M	34.2 M	34.2 M	161 M	161 M	161 M	161 M	149 M	149 M	149 M	149 M	23.8 M	23.8 M	-	-	35 M	-	-	-	13.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency